Lifeline extended: patients get continued access to promising blood disorder drug
NCT ID NCT06173024
Summary
This program allows children and adults with severe Von Willebrand Disease (VWD) to continue receiving an experimental treatment they benefited from in a previous study. It's for patients who have no other good treatment options available in their country and would be harmed if the treatment stopped. The goal is to provide continued access to this medicine until it becomes commercially available or is no longer helpful.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VON WILLEBRAND DISEASE (VWD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.